Evan David Seigerman
Stock Analyst at BMO Capital
(3.77)
# 913
Out of 5,182 analysts
55
Total ratings
54.17%
Success rate
9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRON Disc Medicine | Maintains: Outperform | $120 → $100 | $68.85 | +45.24% | 2 | Feb 17, 2026 | |
| MRK Merck & Co. | Upgrades: Outperform | $82 → $130 | $110.23 | +17.94% | 5 | Dec 18, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $725 → $850 | $744.44 | +14.18% | 9 | Dec 4, 2025 | |
| AMGN Amgen | Maintains: Outperform | $335 → $372 | $340.18 | +9.35% | 5 | Dec 3, 2025 | |
| NVO Novo Nordisk | Maintains: Market Perform | $50 → $46 | $41.20 | +11.65% | 8 | Nov 25, 2025 | |
| REPL Replimune Group | Upgrades: Market Perform | $2 → $11 | $2.68 | +310.45% | 5 | Nov 3, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $215 → $240 | $197.38 | +21.59% | 8 | Sep 12, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $22 → $26 | $27.05 | -3.88% | 2 | Jun 12, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $24 → $28 | $22.30 | +25.56% | 2 | May 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $10.29 | -2.82% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $100 | $45.33 | +120.60% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 → $36 | $26.79 | +34.38% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $3 | $6.29 | -52.31% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $868.27 | -54.39% | 1 | Sep 6, 2022 |
Disc Medicine
Feb 17, 2026
Maintains: Outperform
Price Target: $120 → $100
Current: $68.85
Upside: +45.24%
Merck & Co.
Dec 18, 2025
Upgrades: Outperform
Price Target: $82 → $130
Current: $110.23
Upside: +17.94%
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Outperform
Price Target: $725 → $850
Current: $744.44
Upside: +14.18%
Amgen
Dec 3, 2025
Maintains: Outperform
Price Target: $335 → $372
Current: $340.18
Upside: +9.35%
Novo Nordisk
Nov 25, 2025
Maintains: Market Perform
Price Target: $50 → $46
Current: $41.20
Upside: +11.65%
Replimune Group
Nov 3, 2025
Upgrades: Market Perform
Price Target: $2 → $11
Current: $2.68
Upside: +310.45%
AbbVie
Sep 12, 2025
Maintains: Outperform
Price Target: $215 → $240
Current: $197.38
Upside: +21.59%
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22 → $26
Current: $27.05
Upside: -3.88%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24 → $28
Current: $22.30
Upside: +25.56%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $10.29
Upside: -2.82%
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $45.33
Upside: +120.60%
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $26.79
Upside: +34.38%
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $6.29
Upside: -52.31%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $868.27
Upside: -54.39%